(AOF) – Laboratoires Boiron announces a net income group share up 23.5% to 15.46 million euros in the first half of 2023, for a turnover down 6.6% to 239, 88 million euros. The laboratory adds that its operating profit is down 11.1% over the period to 17.78 million for net cash of 231.18 million, down 4.8% over one year. The group attributes the 6.6% decrease in sales over the half-year in the first place “to the base effect coming from the significant sales of Covid tests in the first half of 2022”.
He also points to “the decline in France in sales of common-name homeopathic medicines”.
The gross margin increased from 67.1% to 72.9% of turnover following the drop in the share of Covid tests in the activity of the semester. Operating expenses increased by 7.25 million euros, taking into account in particular promotional expenses which rose by 5.24 million, particularly in France, Italy and the United States.
Boiron estimates that the evolution of the Group’s sales in 2023 will depend “on the continuation of the current momentum in homeopathic specialties”, as well as “upcoming launches” and the “level of pathology at the end of the year”. . According to management, sales for the year 2023 “could show a slight decline compared to 2022”. However, given the evolution of the product mix and the exceptional adjustments already recorded, operating profit “could be up compared to 2022”.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
